Melissa Hardesty is an Oncology physician affiliated with Alaska Women's Cancer Care. OpenAlex indexes 20 publications with 306 citations (h-index 7).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3851 Piper St Ste U264
Anchorage, AK 995086903
Telephone
907-562-4673Registry record last updated 13 Jan 2016.
Industry payments
20 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- GlaxoSmithKline, LLC.Program year20256 payments
- AstraZeneca Pharmaceuticals LPProgram year20253 payments
- ABBVIE INC.Program year20256 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
27.7%Phenothiazine6.8%Prochlorperazine Maleate63%Compro38%Part D≥19 patientsNonsteroidal Anti-inflammatory Drug5.3%Ibuprofen100%Part D≥29 patients+ 5 more classes in this area
Metabolism & gastrointestinal
20.2%Proton pump inhibitor12.7%Omeprazole100%Part D≥20 patientsSerotonin-3 Receptor Antagonist7.5%Ondansetron Odt73%Ondansetron Hcl27%Part D<11 patientsCancer & immunology
18.2%Aromatase Inhibitor9.7%Letrozole100%Part D≥12 patientsPoly(ADP-Ribose) Polymerase Inhibitor8.5%Lynparza66%Zejula34%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Systemic Treatment of Ovarian Cancer Recurrence: ASCO Living Guideline, Version 2026.1.0
Journal of Clinical Oncology
2026 - Entrectinib use in a platinum-refractory mucinous ovarian cancer harboring a NTRK3 gene fusion
Gynecologic Oncology Reports
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”